Kathryn Haley PhD

Kate hoodI completed my MSc in Translational Oncology at Trinity College Dublin in 2013, and most recently, completed my PhD in Molecular Biology at the University of St Andrews in the UK in 2018.  Currently, in Dr. Ní Chonghaile’s research group, I am investigating the role of epigenetic modulators in resistant Invasive Lobular Carcinoma (ILC) breast cancer. Specifically, I am interested in the role of bromodomain (BRD) proteins in ILC.  I am investigating the therapeutic efficacy of targeting BRD proteins in ILC with the small molecule inhibitor JQ1 in vitro.  I utilise CRISPR-Cas9 technology, microscopy, RNA-seq and BH3 profiling to identify molecular mechanism regulating resistance in ILC.